A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer.
A Phase Ib/II Clinical Study to Evaluate the Efficacy and Safety of TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Participants With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer.
To assess the safety and preliminary efficacy of TQB2930 and chemotherapy with or without bevacizumab in sparticipants with HER2-Abnormally Expressed locally advanced or metastatic colorectal cancer (CRC).
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
- Arzneimittel: TQB2930 injection +(Oxaliplatin for injection + Capecitabine tablets)/( Irinotecan hydrochloride injection+ Capecitabine tablets)+Bevacizumab injection
- Arzneimittel: TQB2930 injection +(Oxaliplatin for injection + Capecitabine tablets)/( Irinotecan hydrochloride injection+ Capecitabine tablets)
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Phase 2
- Phase 1
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Ruihua Xu, Doctor
- Telefonnummer: 020-87343468
- E-Mail: xurh@syscc.org.cn
Studienorte
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100034
- Noch keine Rekrutierung
- Peking University First Hospital
-
Kontakt:
- Shikai Wu, Doctor
- Telefonnummer: 15810037307
- E-Mail: Skywu4923@sina.com
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, China, 400016
- Noch keine Rekrutierung
- The First Affiliated Hospital of Chongqing Medical University
-
Kontakt:
- Tao Zhang, Doctor
- Telefonnummer: 13708311156
- E-Mail: tumorzzt@163.com
-
-
Gansu
-
Lanzhou, Gansu, China, 730050
- Noch keine Rekrutierung
- Gansu Provincial Tumor Hospital
-
Kontakt:
- Zhihu Li, Master
- Telefonnummer: 18993042850
- E-Mail: 245698692@qq.com
-
-
Guangdong
-
Foshan, Guangdong, China, 528000
- Noch keine Rekrutierung
- The First People's Hospital of Foshan
-
Kontakt:
- Wei Wang, Doctor
- Telefonnummer: 18038863618
- E-Mail: wangwei@fsyyy.com
-
Guangzhou, Guangdong, China, 510060
- Rekrutierung
- Sun Yat-sen University Cancer Center
-
Kontakt:
- Ruihua Xu, Doctor
- Telefonnummer: 020-87343468
- E-Mail: xurh@syscc.org.cn
-
Guangzhou, Guangdong, China, 510000
- Noch keine Rekrutierung
- The Sixth Affiliated Hospital, Sun Yat-sen University
-
Kontakt:
- Yanhon Den, Doctor
- Telefonnummer: 13925106525
- E-Mail: dengyanh@mail.sysu.edu.cn
-
-
Guangxi
-
Nanning, Guangxi, China, 530000
- Noch keine Rekrutierung
- Guangxi Zhuang Autonomous Region Cancer Hospital
-
Kontakt:
- Rong Liang, Doctor
- Telefonnummer: 18677070811
- E-Mail: 53371159@qq.com
-
-
Guizhou
-
Zunyi, Guizhou, China, 563000
- Rekrutierung
- The Affiliated Hospital of Zunyi Medical University
-
Kontakt:
- Jiwei Wang, Doctor
- Telefonnummer: 18013964231
- E-Mail: zmu_wangjw@163.com
-
-
Heilongjiang
-
Harbin, Heilongjiang, China, 150000
- Noch keine Rekrutierung
- Harbin Medical University Cancer Hospital
-
Kontakt:
- Tongsen Zheng, Doctor
- Telefonnummer: 15134569619
- E-Mail: zhengtongsen@126.com
-
Kontakt:
- Yuxian Bai, Doctor
- Telefonnummer: 13945095085
- E-Mail: bai_yuxian@126.com
-
Qiqihar, Heilongjiang, China, 161005
- Noch keine Rekrutierung
- Qiqihar First Hospital
-
Kontakt:
- Xiyuan Sun, Doctor
- Telefonnummer: 13945258792
- E-Mail: sunxiyuan2004@126.com
-
-
Henan
-
Zhengzhou, Henan, China, 450000
- Noch keine Rekrutierung
- Henan Cancer Hospital
-
Kontakt:
- Ying Liu, Doctor
- Telefonnummer: 13783604602
- E-Mail: yaya7207@126.com
-
Zhengzhou, Henan, China, 450000
- Noch keine Rekrutierung
- The Third People's Hospital of Zhengzhou
-
Kontakt:
- HaiCun Wang, Master
- Telefonnummer: 13803833783
- E-Mail: whc1975@126.com
-
Zhengzhou, Henan, China, 450000
- Noch keine Rekrutierung
- The first affiliated hospital of Zhengzhou university
-
Kontakt:
- Yongxu Jia, Doctor
- Telefonnummer: 15237128281
- E-Mail: fccjiayx@zzu.edu.cn
-
-
Hubei
-
Jingzhou, Hubei, China, 434099
- Noch keine Rekrutierung
- Jingzhou First People's Hospital
-
Kontakt:
- Yan Hu, Master
- Telefonnummer: 18163137369
- E-Mail: helensparkle@163.com
-
Wuhan, Hubei, China, 430022
- Noch keine Rekrutierung
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
-
Kontakt:
- Hongli Liu, Doctor
- Telefonnummer: 13995680822
- E-Mail: hongliliu@hust.edu.cn
-
-
Hunan
-
Changsha, Hunan, China, 410013
- Rekrutierung
- Hunan Cancer Hospital
-
Kontakt:
- Yi He, Doctor
- Telefonnummer: 18692237222
- E-Mail: heyi@hnca.org.cn
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210008
- Rekrutierung
- Nanjing Drum Tower Hospital
-
Kontakt:
- Yudong Qiu, Doctor
- Telefonnummer: 13951806490
- E-Mail: yudongqiu510@163.com
-
Nanjing, Jiangsu, China, 210009
- Rekrutierung
- Zhongda Hospital Southeast University
-
Kontakt:
- CaiLian Wang, Doctor
- Telefonnummer: 13851756378
- E-Mail: wangcailian65@hotmail.com
-
Nanjing, Jiangsu, China, 210000
- Noch keine Rekrutierung
- Jiangsu Provincial Cancer Hospital
-
Kontakt:
- Yuanhua Liu, Doctor
- Telefonnummer: 13305180356
- E-Mail: yuanhualiu02@hotmail.com
-
-
Jiangxi
-
Nanchang, Jiangxi, China, 330000
- Noch keine Rekrutierung
- Jiangxi Provincal People's Hospital
-
Kontakt:
- Weirong Yao, Doctor
- Telefonnummer: 13907002901
- E-Mail: 13907002901@126.com
-
-
Jilin
-
Changchun, Jilin, China, 130021
- Noch keine Rekrutierung
- Jilin Cancer Hospital
-
Kontakt:
- Hongxia Cui, Master
- Telefonnummer: 13504436090
- E-Mail: 2503074283@qq.com
-
Changchun, Jilin, China, 130021
- Noch keine Rekrutierung
- The first hospital of Jilin University
-
Kontakt:
- Tingting Liang, Doctor
- Telefonnummer: 15804303776
- E-Mail: liangting2006@163.com
-
-
Liaoning
-
Shenyang, Liaoning, China, 110000
- Rekrutierung
- Liaoning Cancer Hospital & Institute
-
Kontakt:
- Jingdong Zhang, Doctor
- Telefonnummer: 18040007878
- E-Mail: 13804027878@163.com
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710000
- Noch keine Rekrutierung
- The First Affiliated Hospital of Xi'an Jiaotong University Medical College
-
Kontakt:
- Aili Suo, Doctor
- Telefonnummer: 18991232561
- E-Mail: Ailisuo@mail.xjtu.edu.cn
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200127
- Rekrutierung
- Renji Hospital, Shanghai Jiao Tong University School of Medicine
-
Kontakt:
- XiuYing Xiao, Doctor
- Telefonnummer: 13564579313
- E-Mail: xiaoxiuying2002@163.com
-
-
Shanxi
-
Xi’an, Shanxi, China, 710000
- Noch keine Rekrutierung
- The Second Affiliated Hospital of Air Force Medical University
-
Kontakt:
- Haichuan Su, Doctor
- Telefonnummer: 18629190366
- E-Mail: cntdgcp@163.com
-
Xi’an, Shanxi, China, 710000
- Noch keine Rekrutierung
- The First Affiliated Hospital of Air Force Medical University
-
Kontakt:
- Yongzhan Nie, Doctor
- Telefonnummer: 15091520001
- E-Mail: nieyongzhan@qq.com
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, China, 300202
- Rekrutierung
- Tianjin Medical University Cancer Institute & Hospital
-
Kontakt:
- Zhanyu Pan, Master
- Telefonnummer: 18622221256
- E-Mail: tjpanzy@126.com
-
Tianjin, Tianjin Municipality, China, 300121
- Noch keine Rekrutierung
- Tianjin Union Medical Center
-
Kontakt:
- Mingqing Zhang, Doctor
- Telefonnummer: 15122875158
- E-Mail: zmq1003@163.com
-
-
Xinjiang
-
Ürümqi, Xinjiang, China, 830054
- Noch keine Rekrutierung
- Xinjiang Medical University Affiliated Tumor Hospital
-
Kontakt:
- YanLi Qu, Master
- Telefonnummer: 18160627963
- E-Mail: quyanli73@163.com
-
-
Zhejiang
-
Lishui, Zhejiang, China, 323000
- Rekrutierung
- Lishui Municipal Central Hospital
-
Kontakt:
- Yanru Xie, Master
- Telefonnummer: 13567615770
- E-Mail: 43437677@qq.com
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Participants voluntarily participate in this study, sign the informed consent form, and have good compliance
- Age: 18-75 years (including the boundary when signing the informed consent form)
- Eastern Cooperative Oncology Group (ECOG) score: 0-1
- Expected survival of more than 3 months
- Unresectable locally advanced or metastatic colorectal cancer diagnosed by histopathology/cytology
- HER2-Abnormally Expressed tested
- Presence of at least one measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
- Participants should agree to use contraception during the study and for 6 months after the end
Exclusion Criteria:
- Participants with previously confirmed Microsatellite Instability Microsatellite Instability-High Deficient Mismatch Repair (MSI-H/dMMR)
- Presence of conditions affecting intravenous, venous blood sampling, or multiple factors affecting oral medications
- Active inflammatory bowel disease within 28 days prior to first dose
- Other malignancies within 5 years prior to the first dose or currently suffering from other malignancies
- Unresolved toxicity greater than CTCAE Grade 1 due to any prior therapy
- Major surgical treatment, significant traumatic injury within 28 days prior to the first dose or anticipation of major surgery during study treatment
- Had wounds or fractures that had not been healed for a long time
- Cerebrovascular accident, deep venous thrombosis and pulmonary embolism within 6 months prior to the first dose
- Patients with a history of psychotropic substance abuse who cannot quit or have mental disorders
- Participants with any severe and/or uncontrolled disease
- Known tumor-related carcinomatous meningitis with symptoms of brain metastases or symptom control for less than 4 weeks
- Patients with imaging suggestive of tumor invasion of major blood vessels or fatal massive hemorrhage due to tumor rupture or invasion of major blood vessels judged by the investigator to be very likely to occur during the study
- Failure to control serous effusions requiring repeated drainage
- Local radiotherapy or 4. Bone marrow irradiation > 30% for bone metastasis before the first medication
- Known tumor-related spinal cord compression, weight-bearing bone pathological fracture, extensive bone metastasis, or uncontrollable tumor bone metastasis-related pain
- Patients who have received chemotherapy, targeted therapy, immunotherapy or other systemic anti-tumor drug therapy before the first medication;
- Received Chinese patent medicine treatment with anti-tumor indications in the package insert of National Medical Products Administration (NMPA) approved drugs before study treatment
- History of live attenuated vaccination before the first dose or planned live attenuated vaccination during the study;
- Previous history of severe allergy of unknown origin
- According to the investigator's judgment, there are concomitant diseases that seriously endanger the participants' safety or affect the completion of the study, or the participant is considered unsuitable for other reasons
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: TQB2930 injection +chemotherapy + Bevacizumab injection
|
TQB2930 enhances the binding to HER2 protein on the surface of tumor cells and increases HER2 internalization by simultaneously targeting ECD2 and ECD4, two non-overlapping epitopes of HER2 protein, which in turn more effectively down-regulates HER2 protein on the surface of tumor cells and dually blocks HER2 signaling. Oxaliplatin can block DNA replication and transcription and induce tumor cell apoptosis. Irinotecan hydrochloride injection inhibits topoisomerase-I via its active metabolite SN-38, prevents religation of DNA single-strand breaks, causes irreversible DNA double-strand damage and induces tumor cell apoptosis. Capecitabine inhibits thymidylate synthase (TS) and interferes with DNA synthesis. Bevacizumab blocks VEGF binding to receptors and inhibits tumor angiogenesis. |
|
Aktiver Komparator: TQB2930 injection +chemotherapy
|
TQB2930 enhances the binding to HER2 protein on the surface of tumor cells and increases HER2 internalization by simultaneously targeting ECD2 and ECD4, two non-overlapping epitopes of HER2 protein, which in turn more effectively down-regulates HER2 protein on the surface of tumor cells and dually blocks HER2 signaling. Oxaliplatin can block DNA replication and transcription and induce tumor cell apoptosis. Irinotecan hydrochloride injection inhibits topoisomerase-I via its active metabolite SN-38, prevents religation of DNA single-strand breaks, causes irreversible DNA double-strand damage and induces tumor cell apoptosis. Capecitabine inhibits thymidylate synthase (TS) and interferes with DNA synthesis. |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Recommended Phase 2 Dose
Zeitfenster: Baseline up to 21 days
|
It refers to the safe and effective dose range that can be used for phase II study determined through phase I clinical trial. |
Baseline up to 21 days
|
|
Adverse event (AE)
Zeitfenster: From the participants signing of the informed consent form to 28 days after the last dose or the start of new anti-tumor therapy (whichever occurs first)
|
Incidence and severity of adverse events. |
From the participants signing of the informed consent form to 28 days after the last dose or the start of new anti-tumor therapy (whichever occurs first)
|
|
Objective Response Rate
Zeitfenster: Baseline up to 24 months
|
The proportion of participants achieving complete response and partial response among the total evaluable cases. |
Baseline up to 24 months
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Half-life
Zeitfenster: Baseline up to 24 months
|
The time it takes for the concentration of a drug in the body (usually the plasma concentration) to decrease to half of its initial value. |
Baseline up to 24 months
|
|
Plasma concentration-time profiles
Zeitfenster: Baseline up to 24 months
|
Total area covered under the curve plotted with time as X-axis and plasma concentration as Y-axis. |
Baseline up to 24 months
|
|
Apparent clearance
Zeitfenster: Baseline up to 24 months
|
The rate at which the drug is cleared from the body. |
Baseline up to 24 months
|
|
Apparent terminal volume of distribution
Zeitfenster: Baseline up to 24 months
|
Describe the drug distribution in the body. |
Baseline up to 24 months
|
|
Trough plasma concentration
Zeitfenster: Baseline up to 24 months
|
Minimum plasma drug concentration level at the end of the dosing interval (before the next dosing). |
Baseline up to 24 months
|
|
Disease Control Rate
Zeitfenster: Baseline up to 24 months
|
The percentage of participants with a complete response, partial response, or stable disease as determined by RECIST 1.1. |
Baseline up to 24 months
|
|
Duration Of Response
Zeitfenster: Baseline up to 24 months
|
The time from the first assessment of the tumor as a complete response or partial response to the first occurrence of disease progression or death from any cause. |
Baseline up to 24 months
|
|
Progression Free Survival
Zeitfenster: Baseline up to 24 months
|
Progression Free Survival (PFS) is defined as the length of time from the start of treatment until the disease progresses or the patient dies from any cause. |
Baseline up to 24 months
|
|
Overall Survival
Zeitfenster: Baseline up to 24 months
|
The time from the start of initial treatment to death from any cause. |
Baseline up to 24 months
|
|
Anti-Drug Antibodies (ADA) incidence
Zeitfenster: Baseline up to 24 months
|
Proportion of anti-drug antibody produced in the population of patients using the drug. |
Baseline up to 24 months
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Neubildungen nach Standort
- Neubildungen
- Darmerkrankungen
- Gastrointestinale Neubildungen
- Neoplasmen des Verdauungssystems
- Erkrankungen des Verdauungssystems
- Magen-Darm-Erkrankungen
- Darmtumoren
- Rektale Erkrankungen
- Darmerkrankungen
- Kolorektale Neubildungen
- Therapeutika
- Routen der Arzneimittelverwaltung
- Arzneimitteltherapie
- Injektionen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- TQB2930-Ib/II-02
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .